The Journal of Practical Medicine >

2023 , Vol. 39 >Issue 16: 2148 - 2152

DOI: https://doi.org/10.3969/j.issn.1006-5725.2023.16.023

Reviews

Research progress on factors and mechanisms of apoptosis of bile duct epithelial cells in primary biliary cholangitis

  • Huanhuan YANG ,
  • Shiyu YUAN ,
  • Yingmei. TANG
Expand
  • Department of Gastroenterology，the Second Affiliated Hospital of Kunming Medical University，Kunming 650101，China

Received date: 2023-05-18

  Online published: 2023-09-26

Fold

Abstract

Primary biliary cholangitis （PBC） is a chronically progressive autoimmune liver disease. At present， There are limited drugs to treat PBC， and some patients eventually progress to end-stage liver disease due to poor response to drugs. The pathogenesis of PBC is not fully understood， but there is increasing evidence that apoptosis of bile duct epithelial cell （BEC） plays an important role in the pathogenesis of PBC. This article reviewed the main factors and related mechanisms affecting BEC apoptosis in PBC， aiming to provide a theoretical basis for developing new therapeutic targets， developing new drugs or proposing new therapeutic schemes for PBC patients.

Key words： primary biliary cholangitis; bile duct epithelial cells; apoptosis; primary biliary cholangitis

Cite this article

Huanhuan YANG , Shiyu YUAN , Yingmei. TANG . Research progress on factors and mechanisms of apoptosis of bile duct epithelial cells in primary biliary cholangitis[J]. The Journal of Practical Medicine, 2023 , 39(16) : 2148 -2152 . DOI: 10.3969/j.issn.1006-5725.2023.16.023

References

1 LI X， LI Y， XIAO J， et al. Unique DUOX2（+）ACE2（+） small cholangiocytes are pathogenic targets for primary biliary cholangitis ［J］. Nat Commun， 2023， 14（1）： 29.
2 ZENG N， DUAN W， CHEN S， et al. Epidemiology and clinical course of primary biliary cholangitis in the Asia-Pacific region： a systematic review and meta-analysis ［J］. Hepatol Int， 2019， 13（6）： 788-799.
3 KOWDLEY K V， BOWLUS C L， LEVY C， et al. Application of the Latest Advances in Evidence-Based Medicine in Primary Biliary Cholangitis ［J］. Am J Gastroenterol， 2023， 118（2）： 232-242.
4 TRIVELLA J， JOHN B V， LEVY C. Primary biliary cholangitis： Epidemiology， prognosis， and treatment ［J］. Hepatol Commun， 2023， 7（6）：e0179.
5 CHEN R， TANG R， MA X， et al. Immunologic Responses and the Pathophysiology of Primary Biliary Cholangitis ［J］. Clin Liver Dis， 2022， 26（4）： 583-611.
6 LLEO A， INVERNIZZI P. Apotopes and innate immune system： novel players in the primary biliary cirrhosis scenario ［J］. Dig Liver Dis， 2013， 45（8）： 630-636.
7 GULAMHUSEIN A F， HIRSCHFIELD G M. Primary biliary cholangitis： pathogenesis and therapeutic opportunities ［J］. Nat Rev Gastroenterol Hepatol， 2020， 17（2）： 93-110.
8 LI H， GUAN Y， HAN C， et al. The pathogenesis， models and therapeutic advances of primary biliary cholangitis ［J］. Biomed Pharmacother， 2021， 140： 111754.
9 ZHANG Y， WANG Y， DING J， et al. Efferocytosis in multisystem diseases （Review） ［J］. Mol Med Rep， 2022， 25（1） ：13.
10 ALLINA J， HU B， SULLIVAN D M， et al. T cell targeting and phagocytosis of apoptotic biliary epithelial cells in primary biliary cirrhosis ［J］. J Autoimmun， 2006， 27（4）： 232-241.
11 LLEO A， LEUNG P S C， HIRSCHFIELD G M， et al. The Pathogenesis of Primary Biliary Cholangitis： A Comprehensive Review ［J］. Semin Liver Dis， 2020， 40（1）： 34-48.
12 RONCA V， MANCUSO C， MILANI C， et al. Immune system and cholangiocytes： A puzzling affair in primary biliary cholangitis ［J］. J Leukoc Biol， 2020， 108（2）： 659-671.
13 MA W T， CHEN D K. Immunological abnormalities in patients with primary biliary cholangitis ［J］. Clin Sci （Lond）， 2019， 133（6）： 741-760.
14 TAYLOR S A， ASSIS D N， MACK C L. The Contribution of B Cells in Autoimmune Liver Diseases ［J］. Semin Liver Dis， 2019， 39（4）： 422-431.
15 ARSENIJEVIC A， STOJANOVIC B， MILOVANOVIC J， et al. Galectin-3 in Inflammasome Activation and Primary Biliary Cholangitis Development ［J］. Int J Mol Sci， 2020， 21（14） ：5097.
16 PRIETO J， BANALES J M， MEDINA J F. Primary biliary cholangitis： pathogenic mechanisms ［J］. Curr Opin Gastroenterol， 2021， 37（2）： 91-98.
17 KAWATA K， KOBAYASHI Y， GERSHWIN M E， et al. The immunophysiology and apoptosis of biliary epithelial cells： primary biliary cirrhosis and primary sclerosing cholangitis ［J］. Clin Rev Allergy Immunol， 2012， 43（3）： 230-241.
18 BERNTSEN N L， FOSBY B， TAN C， et al. Natural killer T cells mediate inflammation in the bile ducts ［J］. Mucosal Immunol， 2018， 11（6）： 1582-1590.
19 CHANG J C， GO S， VERHOEVEN A J， et al. Role of the bicarbonate-responsive soluble adenylyl cyclase in cholangiocyte apoptosis in primary biliary cholangitis； a new hypothesis ［J］. Biochim Biophys Acta Mol Basis Dis， 2018， 1864（4 Pt B）： 1232-1239.
20 VAN NIEKERK J， KERSTEN R， BEUERS U. Role of Bile Acids and the Biliary HCO（3）（-） Umbrella in the Pathogenesis of Primary Biliary Cholangitis ［J］. Clin Liver Dis， 2018， 22（3）： 457-479.
21 RODRIGUES P M， PERUGORRIA M J， SANTOS-LASO A， et al. Primary biliary cholangitis： A tale of epigenetically-induced secretory failure？ ［J］. J Hepatol， 2018， 69（6）： 1371-1383.
22 WANG L， CAO Z M， ZHANG L L， et al. The Role of Gut Microbiota in Some Liver Diseases： From an Immunological Perspective ［J］. Front Immunol， 2022， 13： 923599.
23 LI B， ZHANG J， CHEN Y， et al. Alterations in microbiota and their metabolites are associated with beneficial effects of bile acid sequestrant on icteric primary biliary Cholangitis ［J］. Gut Microbes， 2021， 13（1）： 1946366.
24 TANG R， WEI Y， LI Y， et al. Gut microbial profile is altered in primary biliary cholangitis and partially restored after UDCA therapy ［J］. Gut， 2018， 67（3）： 534-541.
25 TANAKA A， LEUNG P S， GERSHWIN M E. Environmental basis of primary biliary cholangitis ［J］. Exp Biol Med （Maywood）， 2018， 243（2）： 184-189.
26 ZHAO J， ZHAO S， ZHOU G， et al. Altered biliary epithelial cell and monocyte responses to lipopolysaccharide as a TLR ligand in patients with primary biliary cirrhosis ［J］. Scand J Gastroenterol， 2011， 46（4）： 485-494.
27 CHEN W， WEI Y， XIONG A， et al. Comprehensive Analysis of Serum and Fecal Bile Acid Profiles and Interaction with Gut Microbiota in Primary Biliary Cholangitis ［J］. Clin Rev Allergy Immunol， 2020， 58（1）： 25-38.
28 FORMAN H J， ZHANG H. Targeting oxidative stress in disease： promise and limitations of antioxidant therapy ［J］. Nat Rev Drug Discov， 2021， 20（9）： 689-709.
29 WASIK U， MILKIEWICZ M， KEMPINSKA-PODHORODECKA A， et al. Protection against oxidative stress mediated by the Nrf2/Keap1 axis is impaired in Primary Biliary Cholangitis ［J］. Sci Rep， 2017， 7： 44769.
30 SASAKI M， IKEDA H， NAKANUMA Y. Activation of ATM signaling pathway is involved in oxidative stress-induced expression of mito-inhibitory p21WAF1/Cip1 in chronic non-suppurative destructive cholangitis in primary biliary cirrhosis： an immunohistochemical study ［J］. J Autoimmun， 2008， 31（1）： 73-78.
31 PRAWAN A， BURANRAT B， KUKONGVIRIYAPAN U， et al. Inflammatory cytokines suppress NAD（P）H：quinone oxidoreductase-1 and induce oxidative stress in cholangiocarcinoma cells ［J］. J Cancer Res Clin Oncol， 2009， 135（4）： 515-522.
32 HARADA K， ISSE K， KAMIHIRA T， et al. Th1 cytokine-induced downregulation of PPARgamma in human biliary cells relates to cholangitis in primary biliary cirrhosis ［J］. Hepatology， 2005， 41（6）： 1329-1338.
33 LLEO A， WANG G Q， GERSHWIN M E， et al. Primary biliary cholangitis ［J］. The Lancet， 2020， 396（10266）： 1915-1926.
34 ARSENIJEVIC A， MILOVANOVIC M， MILOVANOVIC J， et al. Deletion of Galectin-3 Enhances Xenobiotic Induced Murine Primary Biliary Cholangitis by Facilitating Apoptosis of BECs and Release of Autoantigens ［J］. Sci Rep， 2016， 6： 23348.
35 CHEN Y， GUO G， GUO S， et al. Intracellular B7-H4 suppresses bile duct epithelial cell apoptosis in human primary biliary cirrhosis ［J］. Inflammation， 2011， 34（6）： 688-697.
Options
Outlines

/

〈 〉